Integrating Pharmacogenomics into Routine Prescribing in Brisbane Hospitals

A medicine can be highly effective for one person and poorly tolerated by another. Pharmacogenomics examines how inherited genetic differences influence the way patients absorb, process and respond to medicines. Used carefully, it can help clinicians select a safer drug, adjust a dose or avoid an adverse reaction before treatment begins.

A pilot across Brisbane hospitals would provide a practical test of whether genomic information can move from specialist research into everyday prescribing. The work fits Brisbane Diamantina Health Partners’ focus on health translation: connecting universities, research institutes and health services so that useful evidence reaches patients, families, carers and communities.

Why Prescribing Needs A Genetic Lens

Many medicines are broken down by enzymes whose activity varies between individuals. Differences in genes such as CYP2C19, CYP2D6, TPMT and DPYD can affect antidepressants, pain medicines, immunosuppressants and some cancer treatments. A standard dose may therefore be too strong, too weak or more likely to cause toxicity for a particular patient.

Pharmacogenomic testing is not a crystal ball. It does not replace a medication history, pathology results, clinical assessment or shared decision-making. Age, kidney and liver function, pregnancy, smoking, diet and interactions with other medicines remain important. The value lies in adding a reliable piece of information when the likely benefit is clinically meaningful.

What A Brisbane Pilot Would Test

The pilot could begin with prescribing situations where evidence and clinical need are both strong. Examples include patients starting selected antidepressants after previous treatment problems, people receiving medicines with serious toxicity risks, and patients taking multiple drugs after discharge from hospital. A focused scope would make it easier to train staff, monitor outcomes and refine the model before expanding it.

Possible sites could include services linked with the Royal Brisbane and Women’s Hospital, Princess Alexandra Hospital and other Metro North or Metro South settings, with laboratory support from Queensland’s public pathology system. The pilot could compare usual care with a pharmacist-supported pathway that offers testing, interprets results and records recommendations in the electronic medical record.

The process should be designed alongside clinicians who prescribe under pressure. Education modules for clinicians can support a common understanding of research translation, while case-based teaching helps doctors, pharmacists and nurses recognise when a genetic result is actionable rather than merely interesting.

Building A Safe Clinical Workflow

A workable pathway starts when a clinician identifies a suitable patient and explains the purpose, limits and possible consequences of testing. After consent, a saliva or blood sample is collected, analysed by an accredited laboratory and reported using recognised clinical guidelines. The result should state what action, if any, is recommended and how confident the evidence is.

Results need to be visible at the point of prescribing, not buried in a PDF or stored in a separate research database. Decision support could provide an alert when a relevant medicine is ordered, with a concise recommendation and a link to detailed evidence. Alerts must be selective: too many warnings create fatigue and can cause staff to ignore important prompts.

A pharmacist or pharmacogenomics-trained clinician could review complex cases, particularly where several genes, medicines or comorbidities are involved. Clear escalation arrangements would help junior staff and after-hours teams know who can interpret an uncertain result. Any workflow should also allow patients to carry a copy of their result when moving between hospital, general practice, community pharmacy and private care.

Choosing Medicines And Patients

A pilot should define eligibility before testing begins. Broad “test everyone” strategies may generate results that are difficult to interpret and may offer little immediate value. Targeted testing is more likely to demonstrate whether pharmacogenomics improves prescribing, reduces avoidable harm or shortens the time taken to find an effective treatment.

Outcomes could include adverse drug reactions, hospital readmissions, treatment changes, symptom improvement, time to therapeutic stability and clinician confidence. In mental health, for example, the relevant measure may be fewer medication changes and better continuity of care, rather than a genetic result alone. Work examining treatment-resistant depression research also shows why emerging treatments need careful evidence, governance and patient-centred evaluation.

The pilot should distinguish between a genetic finding that changes prescribing today and one that may become useful later. Results should be reviewed against current Australian and international guidance, because evidence, drug labels and clinical recommendations can change. A governance group can oversee updates and prevent outdated advice from remaining active in hospital systems.

Equity, Consent And Data Governance

Genomic services must work for Queensland’s diverse population, including Aboriginal and Torres Strait Islander communities, culturally and linguistically diverse families, older people and patients living in regional or remote areas. A Brisbane pilot should involve consumers and community representatives early, use plain Australian English, provide interpreters where needed and avoid presenting testing as compulsory or universally beneficial.

Consent needs to cover the clinical purpose of the test, possible future use of the result, privacy protections and the limits of what may be discovered. Pharmacogenomic testing generally focuses on medicine response, yet patients may still have concerns about family implications, data storage or discrimination. These concerns deserve a clear explanation rather than a rushed signature on a form.

Data should be managed under Queensland Health requirements, Australian privacy law and relevant ethics and governance processes. Research data and clinical data need defined boundaries, with role-based access, audit trails and transparent retention policies. Partnerships with universities and laboratories should specify who can use de-identified information and how patients can withdraw from optional research.

Measuring Value Beyond The First Prescription

A successful pilot should demonstrate more than technical accuracy. It should show whether the service improves care that matters to patients: fewer harmful side effects, faster recovery, better medication adherence and less frustration during repeated prescribing changes. Economic analysis can examine test costs against avoided admissions, emergency presentations and ineffective treatment.

Implementation findings are equally important. The team should record turnaround times, sample failure rates, clinician uptake, alert overrides, patient understanding and differences in access between hospital services. These measures reveal whether a promising intervention can function in a busy Queensland health system rather than only in a research setting.

The pathway from discovery to routine care requires evidence, governance, workforce capability and sustained funding. A clear lab-to-bedside pathway can help project teams identify what must happen between a validated genetic association and a safe prescribing change. It also keeps expectations realistic: implementation is a staged process, not a single technology purchase.

Brisbane hospitals, researchers, pharmacists, clinicians and consumer partners can use the pilot to build an Australian evidence base for precision prescribing. Register your interest with the relevant health service or research partnership, contribute patient and clinician priorities, and support evaluation that makes genomic medicine safer, fairer and useful at the bedside.